Communiqués Novartis AG

Actions

NOVN

CH0012005267

Produits pharmaceutiques

Marché Fermé - Swiss Exchange Autres places de cotation 17:30:12 05/06/2026			Varia. 5j.	Varia. 1 janv.
117,98 ^CHF	+1,85 %		+0,14 %	+7,65 %

05/06	Bourse Zurich: le SMI termine la semaine sans entrain	AW
05/06	Flerie réaffirme sa confiance dans l'anticancéreux de Xspray Pharma après une réponse de la FDA	MT

Communiqués

04/06	Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years	GL
03/06	Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients	GL
01/06	Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML	GL
01/06	Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases	GL
31/05	Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer	GL
26/05	New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength	GL
21/05	Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA	GL
17/05	New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer	GL
11/05	Medicines, Monopolies, And Justice: India’s Fight For Fair Patents	AQ
07/05	Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities	GL
07/05	Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities	GL
05/05	Novartis : Earnings Document (novartis q1 2026 impact and sustainability update)	PU
30/04	Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility	GL
30/04	Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility	GL
28/04	Novartis: Q1 Earnings Snapshot	AQ
28/04	Novartis : Earnings Document (q1 2026 interim financial report en)	PU
28/04	Novartis : Earnings Document (q1 2026 investor presentation)	PU
28/04	Novartis : Earnings Document (novartis target patient populations 2026)	PU
28/04	Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed	GL
27/04	Novartis malaria treatment Coartem Baby receives WHO prequalification, paving way for greater access for newborns and young infants	AQ
27/04	Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria	GL
24/04	Novartis : withdraws EMA application for adding new indication for Pluvicto®	PU
24/04	Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)	GL
24/04	Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants	GL
24/04	Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants	GL